Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Complement c3 inhibitors
11 evidence topics · 6 sources
Pegcetacoplan: mechanism and FDA approval
“On February 17, 2023, pegcetacoplan 15 mg (Syfovre, Apellis Pharmaceuticals) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegcetacoplan is a polyethylene-glycolylated (PEGylated) peptide that blocks complement factor C3, which has been implicated in the development of both the exudative and advanced atrophic forms of AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pegcetacoplan: indication, dosage, and contraindications
Pegcetacoplan: retinal vasculitis and retinal vascular occlusion warning
Pegcetacoplan: neovascular AMD, intraocular inflammation, and ischemic optic neuropathy
OAKS and DERBY: design
OAKS and DERBY: GA lesion growth from baseline to month 24
| Study and group | Rate of GA lesion area growth (mm2), slope (SE) | Difference (95% CI) in slope from sham pooled | Percent difference from sham pooled |
|---|---|---|---|
| OAKS, pegcetacoplan monthly | “3.11 (0.148)” | “−0.87”“(−1.27 to −0.47)” | “−21.9%” |
| OAKS, pegcetacoplan every other month | “3.26 (0.134)” | “−0.72”“(−1.10 to −0.33)” | “−18.1%” |
| OAKS, sham pooled | “3.98 (0.143)” | “NA” | “NA” |
| DERBY, pegcetacoplan monthly | “3.28 (0.125)” | “−0.73”“(−1.14 to −0.31)” | “−18.1%” |
| DERBY, pegcetacoplan every other month | “3.31 (0.129)” | “−0.70”“(−1.11 to −0.28)” | “−17.4%” |
| DERBY, sham pooled | “4.00 (0.169)” | “NA” | “NA” |
OAKS and DERBY: primary endpoint at month 12 and visual function endpoints
“The primary endpoint was the change from baseline to month 12 in the total area of geographic atrophy lesions in the study eye based on fundus autofluorescence imaging” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In DERBY, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not reach significance, by 12%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no differences in key secondary visual function endpoints at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
OAKS and DERBY: guideline summary of lesion growth reductions
GALE open-label extension: up to 36 months of pegcetacoplan
“Through the first 12 months of GALE, 92.0% (727/790) patient retention was observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No events of vasculitis were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GALE open-label extension: up to 48 months, early versus delayed treatment
“The delayed treatment group included sham-observed eyes from OAKS and DERBY which crossed over at 24 months to receive pegcetacoplan treatment for 24 months in the GALE OLE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, 48 continuous months of pegcetacoplan treatment reduced GA area growth rate by up to 24% compared with projected sham, translating to 1.88 mm2 of retinal tissue.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GALE safety data were consistent with the findings of the OAKS and DERBY studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegcetacoplan: postmarketing retinal vasculitis case series
“Fourteen eyes of 13 patients were confirmed to have retinal vasculitis by review of imaging studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All cases occurred after the first pegcetacoplan injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Occlusive retinal vasculopathy was confirmed in 11 eyes (79%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight eyes (57%) had more than a 3-line decrease in VA, and 6 eyes (43%) had more than a 6-line decrease in VA from baseline to the final follow-up, including 2 eyes that were enucleated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote